Blueprint's (Most Recent) Raise
- Closed: TBD (proposed pricing on 1/22/20)
- Pricing: $69.00/share
- Amount: ~$325 million
- Over-allotment: TBD
Blueprint Medicines (BPMC) recently announced a dilutive raise, sending share prices below key moving averages:
Blueprint's last raise was in March 2019 and priced at $74/share, $5/share higher than the most recent offering. Of course, this is never favorable, but in this case may be a necessary desperation. The company figures to increase an already good amount of R&D spending. Couple this with commercialization pegged to begin this year and you have the need for